Skip to content

Novartis’s Canakinumab Fails in Another Lung Cancer Trial

Novartis AG said a late-stage trial of experimental lung-cancer drug canakinumab failed, likely the last blow for a repurposed medicine that had already failed in one lung cancer study last year. 

Canakinumab, which is used to treat a type of arthritis in children, didn’t help lung-cancer patients live longer without disease after surgery than placebo, the Basel, Switzerland-based drugmaker said Monday. Last year, the drug failed when paired with immune therapy and chemotherapy in a different group of patients.